サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：注射型ドラッグデリバリーの世界市場-2023年～2030年
市場調査レポート
商品コード
1297776

注射型ドラッグデリバリーの世界市場-2023年～2030年

Global Injectable Drug Delivery Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
注射型ドラッグデリバリーの世界市場-2023年～2030年
出版日: 2023年06月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

注射型ドラッグデリバリーの世界市場は、2022年に6,073億米ドルに達し、2030年には1兆3,641億米ドルに達し、有利な成長が予測されています。注射型ドラッグデリバリー市場は、2023-2030年の予測期間中に10.9%のCAGRを示すと予想されます。

継続的な技術革新は、特定のリマインダー、デバイスの自己使用、スマートフォンの接続性などの助けを借りて、注射型ドラッグデリバリー中の患者の経験を改善するために課せられています。さらに、ペン型注射器や無針注射器などの現在の自己注射デバイスは、注射型ドラッグデリバリーを比較的容易にしています。

注射剤とは、注射によって体内に投与される薬剤のことです。注射剤の開発・承認件数の増加などが、予測期間中の注射型ドラッグデリバリー世界市場の成長を後押ししています。

市場力学

市場開拓の増加が予測期間中の注射型ドラッグデリバリーの世界市場成長を牽引

製品イントロダクション、製品承認、買収、提携、合併、拡大、投資などの新興国市場の増加が、予測期間中の注射型ドラッグデリバリーの世界市場の成長を促進しています。

例えば、2022年2月、日本の多国籍製薬企業である武田薬品は、成人および小児患者（12歳以上）における遺伝性血管性浮腫（HAE）のエピソードを回避するために使用されるタキヒロ（ラナデルマブ-フライオ）注射剤単回投与プレフィルドシリンジ（PFS）について、米国FDAの承認を取得しました。

老年人口の増加が世界の注射型ドラッグデリバリー市場に有望な成長機会をもたらす

非経口ドラッグデリバリーは、治療指数が狭い、あるいは経口バイオアベイラビリティが低い薬剤の治療濃度を達成・維持するために、老年人口に広く利用されています。このように、老年人口の増加は、今後数年間の世界市場に将来の成長機会をもたらします。

例えば、国連の「World Population Prospects 2022」によると、80歳以上の人口は2022年の1億5700万人から2050年には3倍の4億5900万人に増加すると予測されています。

ロシア・ウクライナ戦争の影響分析

ロシアがウクライナに侵攻して以来、ロシア・ウクライナ戦争は市場に悪影響を及ぼしています。292件の攻撃により、218の病院や診療所が損壊・破壊され、救急車への攻撃は65件以上、血液センター、歯科診療所、薬局などその他の医療インフラへの攻撃は181件に及んでいます。

世界不況の影響分析

世界中でインフレが進行し、世界の注射型ドラッグデリバリー市場に大きな影響を与えています。ほとんどの製薬会社は原材料価格の上昇を観察しており、利益率の低下を予想しています。

ヘルスケア市場は、ジェネリック医薬品や処方箋医薬品の価格に関しては、かなりコントロールされています。それにもかかわらず、製薬企業は薬価に対するストレスが高まっています。このような価格設定のひずみの主な原因は、インフレ率の上昇であり、世界市場の成長に悪影響を及ぼしています。

人工知能の影響分析

人工知能は、製品開発の増加により、世界の注射型ドラッグデリバリー市場にプラスの影響を与えています。例えば、ある研究者グループは、グーグルのAIベンチャーであるDeepMindを活用して、がん殺傷薬や遺伝子治療薬などのタンパク質をヒト細胞に直接注入できる細菌注入システムを設計しました。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 製品の進歩
      • 市場開拓
    • 抑制要因
      • 針刺し事故
      • 代替ドラッグデリバリーシステムの使用の増加
    • 機会
    • 政府の取り組み
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 世界不況分析

第9章 人工知能の影響分析

第10章 製品タイプ別

  • デバイス
    • 従来の注射デバイス
    • 自己注射器
    • 自動注射器
    • ペン型注射器
    • ウェアラブル注射器
    • その他の器具
  • 製剤
    • 従来のドラッグデリバリー製剤
      • 溶液製剤
      • 再構成/凍結乾燥製剤
      • 懸濁製剤
      • 乳剤
    • 新規薬剤製剤
      • ニオソーム
      • リポソーム
      • 高分子/混合セル
      • マイクロ粒子

第11章 包装別

  • バイアル
  • アンプル
  • ボトル
  • カートリッジ
  • その他

第12章 治療用途別

  • 自己免疫疾患
  • ホルモン疾患
  • 希少疾患
  • がん
  • その他の治療疾患

第13章 投与経路別

  • 皮内
  • 中枢神経系
  • その他

第14章 流通チャネル別

  • オンライン薬局
  • 小売薬局
  • 病院薬局
  • その他

第15章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • ロシア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第16章 競合情勢

  • 競合シナリオ
  • 市場シェア分析
  • M&A分析

第17章 企業プロファイル

  • Becton Dickinson & Company
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Baxter International, Inc.
  • Gerresheimer AG
  • Pfizer, Inc.
  • Schott AG
  • ELI Lilly and Company
  • Sandoz（A Division of Novartis AG）
  • Terumo Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Corning Incorporated

第18章 付録

目次
Product Code: MD799

Market Overview

The Global Injectable Drug Delivery Market reached USD 607.3 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 1,364.1 billion by 2030. The injectable drug delivery market is expected to exhibit a cagr of 10.9% during the forecast period 2023-2030.

Continuous innovations are subjected to improve patients' experience during injectable drug delivery with the help of certain reminders, the self-use of devices, connectivity of smartphones, and others. Moreover, the current self-injection devices, including pen and needle-free injectors, have made injectable drug delivery comparatively easier.

An injectable is any medication dispensed into the body via injections. The increasing number of injectable product development and approvals, among other factors, are driving the growth of the Global Injectable Drug Delivery Market during the forecast period.

Market Dynamics

The Increasing Number of Market Developments is Driving the Global Injectable Drug Delivery Market Growth in the Forecast Period

The increasing market developments, such as product introductions, product approvals, acquisitions, collaborations, mergers, expansion, and investments, among others, are driving the growth of the global injectable drug delivery market during the forecast period.

For instance, in February 2022, Takeda, a Japanese multinational pharmaceutical corporation, acquired US FDA authorization for its TAKHZYRO (lanadelumab-flyo) injection single-dose prefilled syringe (PFS) utilized to avert episodes of hereditary angioedema (HAE) in adult and pediatric patients (12 years and above).

The Growing Geriatric Population is Providing the Global Injectable Drug Delivery Market with Prospective Growth Opportunities

Parenteral drug delivery is vastly utilized for geriatrics to attain and sustain a therapeutic concentration of medications with a narrow therapeutic index or poor oral bioavailability. Thus, the growing geriatric population presents the global market with future growth opportunities in the upcoming years.

For instance, according to the World Population Prospects 2022, from the UN, the number of individuals aged 80 or above is anticipated to grow triple fold, from 157 million in 2022 to 459 million by 2050.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with Pricing Dynamics (Including pricing change during and post-pandemic comparing it to pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), Government Initiatives (Initiatives to revive market, sector or Industry by Government Bodies) and Manufacturers Strategic Initiatives (What manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine War Impact Analysis

The Russia-Ukraine war has had a negative influence on the market since the Russian invasion of Ukraine with 292 attacks has damaged or destroyed 218 hospitals and clinics, over 65 attacks on ambulances, and 181 attacks on other health infrastructure, like blood centers, dental clinics, and pharmacies.

Global Recession Impact Analysis

All over the globe, climbing inflation is considerably impacting the Global Injectable Drug Delivery Market. Most pharmaceutical corporations are observing elevated prices for raw materials and are anticipating a reduction in profit margins.

The healthcare market is significantly controlled when it arrives to the pricing of generic and prescription medicines. Nevertheless, pharma corporations are encountering growing stress on drug pricing. The primary cause for this growing pricing strain is the elevated rate of inflation negatively impacting global market growth.

Artificial Intelligence Impact Analysis

Artificial intelligence is having a positive impact on the global injectable drug delivery market owing to increasing product developments. For instance, a group of investigators has harnessed Google`s AI venture DeepMind to design a bacterial injection system that can inject proteins, such as cancer-killing medicines and gene treatments, directly into human cells.

Segment Analysis

The Global Injectable Drug Delivery Market is segmented based on product type, packaging, therapeutic application, route of administration, distribution channel, and region.

The Hormonal Therapeutic Application Segment is Estimated to Hold highest Share of the Global Market.

Owing to the increasing product approvals for hormonal disorders and growing cases of hormonal disorders the hormonal therapeutic application segment is estimated to hold 30.9% of the global injectable drug delivery market.

For instance, in July 2022, European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a favorable view and suggested consent for the usage of Mounjaro (tirzepatide) auto-injector pen for type 2 diabetes. Moreover, the 2022 National Diabetes Statistics Report by CDC estimated that over 130 million adults with diabetes or prediabetes in the United States.

Geographical Analysis

Europe is Estimated to Hold the Second-Largest Share of the Global Injectable Drug Delivery Market During the Forecast Period

Owing to the increasing product approvals in Europe, the region is estimated to be around 29.6% of the global injectable drug delivery market by 2030.

For instance, in February 2021, Xeris Pharmaceuticals acquired authorization from the European Commission (EC) for its Ogluo (glucagon) pre-filled pen indicated for treating extreme hypoglycemia in children, adults, and adolescents aged 2 years and over with diabetes mellitus.

Competitive Landscape

The major global players in the market include: Becton Dickinson & Company, Baxter International, Inc., Gerresheimer AG, Pfizer, Inc., Schott AG, Eli Lilly and Company, Sandoz, Terumo Corporation, Teva Pharmaceutical Industries Ltd, Corning Incorporated, among others.

Why Purchase the Report?

  • To visualize the Global Injectable Drug Delivery Market segmentation based on product type, packaging, therapeutic application, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous injectable drug delivery market-level data points with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Injectable Drug Delivery Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Packaging
  • 3.3. Snippet by Therapeutic Application
  • 3.4. Snippet by Route of Administration
  • 3.5. Snippet by Distribution Channel
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Product Advancements
      • 4.1.1.2. Market Developments
    • 4.1.2. Restraints
      • 4.1.2.1. Needle Stick injuries
      • 4.1.2.2. The Increasing Use of Alternative Drug Delivery Systems
    • 4.1.3. Opportunity
    • 4.1.4. Government Initiatives
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 & Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Product Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.1.2. Market Attractiveness Index, By Product Type
  • 10.2. Devices
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 10.2.3. Conventional injection devices
    • 10.2.4. Self-injection devices
    • 10.2.5. Autoinjectors
    • 10.2.6. Pen Injectors
    • 10.2.7. Wearable injectors
    • 10.2.8. Other devices
  • 10.3. Formulations
    • 10.3.1. Conventional drug delivery formulation
      • 10.3.1.1. Solutions
      • 10.3.1.2. Reconstituted/Lyophilized Formulations
      • 10.3.1.3. Suspensions
      • 10.3.1.4. Emulsions
    • 10.3.2. Novel drug formulations
      • 10.3.2.1. Niosomes
      • 10.3.2.2. Liposomes
      • 10.3.2.3. Polymeric/mixed cells
      • 10.3.2.4. Microparticles

11. By Packaging

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 11.1.2. Market Attractiveness Index, By Packaging
  • 11.2. Vials*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Ampule
  • 11.4. Bottle
  • 11.5. Cartridges
  • 11.6. Others

12. By Therapeutic Application

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
    • 12.1.2. Market Attractiveness Index, By Therapeutic Application
  • 12.2. Autoimmune Disease
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Hormonal Disorders
  • 12.4. Orphan disease
  • 12.5. Cancer
  • 12.6. Other therapeutic diseases

13. By Route of Administration

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.1.2. Market Attractiveness Index, By Route of Administration
  • 13.2. Intradermal
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 13.3. Central Nervous System
  • 13.4. Others

14. By Distribution Channel

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 14.1.2. Market Attractiveness Index, By Distribution Channel
  • 14.2. Online Pharmacies
    • 14.2.1. Introduction
    • 14.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 14.3. Retail pharmacies
  • 14.4. Hospital Pharmacies
  • 14.5. Others

15. By Region

  • 15.1. Introduction
    • 15.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 15.1.2. Market Attractiveness Index, By Region
  • 15.2. North America
    • 15.2.1. Introduction
    • 15.2.2. Key Region-Specific Dynamics
    • 15.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 15.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 15.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application
    • 15.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 15.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 15.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 15.2.8.1. The U.S.
      • 15.2.8.2. Canada
      • 15.2.8.3. Mexico
  • 15.3. Europe
    • 15.3.1. Introduction
    • 15.3.2. Key Region-Specific Dynamics
    • 15.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 15.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 15.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application
    • 15.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 15.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 15.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 15.3.8.1. Germany
      • 15.3.8.2. The U.K.
      • 15.3.8.3. France
      • 15.3.8.4. Italy
      • 15.3.8.5. Russia
      • 15.3.8.6. Rest of Europe
  • 15.4. South America
    • 15.4.1. Introduction
    • 15.4.2. Key Region-Specific Dynamics
    • 15.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 15.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 15.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application
    • 15.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 15.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 15.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 15.4.8.1. Brazil
      • 15.4.8.2. Argentina
      • 15.4.8.3. Rest of South America
  • 15.5. Asia-Pacific
    • 15.5.1. Introduction
    • 15.5.2. Key Region-Specific Dynamics
    • 15.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 15.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 15.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application
    • 15.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 15.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 15.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 15.5.8.1. China
      • 15.5.8.2. India
      • 15.5.8.3. Japan
      • 15.5.8.4. Australia
      • 15.5.8.5. Rest of Asia-Pacific
  • 15.6. Middle East and Africa
    • 15.6.1. Introduction
    • 15.6.2. Key Region-Specific Dynamics
    • 15.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 15.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 15.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application
    • 15.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 15.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

16. Competitive Landscape

  • 16.1. Competitive Scenario
  • 16.2. Market Share Analysis
  • 16.3. Mergers and Acquisitions Analysis

17. Company Profiles

  • 17.1. Becton Dickinson & Company
    • 17.1.1. Company Overview
    • 17.1.2. Product Portfolio and Description
    • 17.1.3. Financial Overview
    • 17.1.4. Key Developments
  • 17.2. Baxter International, Inc.
  • 17.3. Gerresheimer AG
  • 17.4. Pfizer, Inc.
  • 17.5. Schott AG
  • 17.6. ELI Lilly and Company
  • 17.7. Sandoz (A Division of Novartis AG)
  • 17.8. Terumo Corporation
  • 17.9. Teva Pharmaceutical Industries Ltd.
  • 17.10. Corning Incorporated

LIST NOT EXHAUSTIVE

18. Appendix

  • 18.1. About Us and Services
  • 18.2. Contact Us